—I appreciate the comments by Weller and Kornhuber on our article.1 Although we confined our review to the potential use of N-methyl-d-aspartate (NMDA) antagonists in Parkinson's disease only, we certainly agree with the notion that these agents may be beneficial in other conditions. While it is well known that sudden withdrawal of dopaminergic antiparkinsonian medications may precipitate neuroleptic malignant syndrome (NMS),2 it is less widely appreciated that abrupt cessation of amantadine (a commonly used antiparkinsonian medication and a noncompetitive NMDA antagonist) may be associated with a profound exacerbation of parkinsonism3 and a condition marked by severe rigidity (J.T.G., unpublished observations, 1992), even with continued therapy with levodopa or a dopamine agonist. Could this represent a forme fruste or variant of NMS? Perhaps the full NMS is not seen in these cases because of the fact that there is ongoing dopaminergic therapy. It
Greenamyre JT. N-Methyl-D-Aspartate Antagonists, Schizophrenia, and Neuroleptic Malignant Syndrome-Reply. Arch Neurol. 1992;49(9):901. doi:10.1001/archneur.1992.00530330018008
Neurology in JAMA: Read the Latest
Customize your JAMA Network experience by selecting one or more topics from the list below.